Biontech Se ADR (BNTX)

$107.48 -2.75 (-2.49%)
Market Cap 24.82B
Revenue (ttm) 2.98B
Net Income (ttm) -719.92M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -24.18%
Debt to Equity Ratio 0.01
Volume 599,500
Avg Vol 946,468
Day's Range N/A - N/A
Shares Out 225.18M
Stochastic %K 69%
Beta 1.49
Analysts Strong Sell
Price Target $141.25

Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical tri...

Industry: Biotechnology
Sector: Healthcare
Phone: 49 6131 9084
Fax: 49 6131 9084
Address:
An der Goldgrube 12, Mainz, Germany
taxplanr
taxplanr Mar. 3 at 1:00 AM
Ovarian Cancer Free in 4 months with Ivermectin and Mebendazole in Australia $BNTX $MRNA $BMY $MRK https://makisw.substack.com/p/ivermectin-and-mebendazole-testimonial-214?utm_source=post-email-title&publication_id=1385328&post_id=189706231&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
taxplanr
taxplanr Mar. 3 at 12:58 AM
$BNTX $MRNA how did I miss this? 😁 https://finviz.com/news/317385/moderna-faces-lawsuit-from-biontech-over-next-generation-covid-19-shot
0 · Reply
taxplanr
taxplanr Mar. 3 at 12:53 AM
Ivermectin and Fenbendazole taking care of Lymphona in Canada $BNTX $MRNA $BMY $MRK https://makisw.substack.com/p/ivermectin-and-fenbendazole-testimonial-c15?utm_source=post-email-title&publication_id=1385328&post_id=189650154&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
taxplanr
taxplanr Mar. 2 at 8:56 PM
Ivermectin and Fenbendazole shrinking Pancreatic Cancer Tumors in Slovakia $BNTX $MRNA $BMY $MRK https://makisw.substack.com/p/ivermectin-and-fenbendazole-testimonial-c15?utm_source=post-email-title&publication_id=1385328&post_id=189650154&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
RichMitch
RichMitch Mar. 2 at 8:39 PM
$GOSS That .35 was delicious. Yeah, Im'ma Hold this one $BNTX $UNH $LLY $SPY
0 · Reply
IndyOne
IndyOne Mar. 2 at 7:35 PM
$BNTX BioNTech (BNTX) Expected to Announce Quarterly Earnings on Monday
0 · Reply
taxplanr
taxplanr Mar. 2 at 6:38 PM
$BNTX $MRNA $BMY $MRK
1 · Reply
Ventureville
Ventureville Mar. 2 at 4:47 PM
$BIOV.CSE $BVAXF $MRNA $BNTX This is being mispriced. Biovaxys isn’t competing with PD-1, it’s targeting the patients those therapies fail, right as the class hits a 2028 patent cliff. That’s partnership territory, not head-to-head risk. Comparable deals: $50M–$200M. Current cap: ~CAD $7M. One deal changes everything.
1 · Reply
taxplanr
taxplanr Mar. 2 at 3:35 PM
$BNTX $MRNA $PFE
1 · Reply
taxplanr
taxplanr Mar. 2 at 3:17 PM
CBD Oil working with Ivermectin and Mebendazole on Glioblastoms $BNTX $MRNA $BMY $MRK https://makisw.substack.com/p/ivermectin-mebendazole-cbd-oil-testimonial-9b7?utm_source=post-email-title&publication_id=1385328&post_id=189569450&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
Latest News on BNTX
BioNTech: The Market Is Pricing Low Oncology Success

Feb 25, 2026, 9:46 AM EST - 5 days ago

BioNTech: The Market Is Pricing Low Oncology Success

BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026

Feb 24, 2026, 6:45 AM EST - 6 days ago

BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026

BioNTech sues Moderna for patent infringement over COVID-19 shots

Feb 19, 2026, 1:25 PM EST - 11 days ago

BioNTech sues Moderna for patent infringement over COVID-19 shots

MRNA

BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer

Jan 28, 2026, 8:00 AM EST - 4 weeks ago

BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer

BioNTech SE (BNTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 10:45 PM EST - 6 weeks ago

BioNTech SE (BNTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 6:45 AM EST - 7 weeks ago

BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference

University of Pennsylvania, BioNTech, and OUP Launch $50 Million Life Sciences Fund

Jan 9, 2026, 10:00 AM EST - 7 weeks ago

University of Pennsylvania, BioNTech, and OUP Launch $50 Million Life Sciences Fund

BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field

Dec 18, 2025, 4:45 AM EST - 2 months ago

BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field

BioNTech: Maintaining "Strong Buy" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart

Dec 9, 2025, 5:54 PM EST - 2 months ago

BioNTech: Maintaining "Strong Buy" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

Dec 9, 2025, 7:00 AM EST - 2 months ago

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

BMY

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

Dec 6, 2025, 3:30 PM EST - 3 months ago

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

BioNTech Achieves Minimum Condition in CureVac Exchange Offer

Dec 3, 2025, 9:01 AM EST - 3 months ago

BioNTech Achieves Minimum Condition in CureVac Exchange Offer

CVAC

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

Dec 1, 2025, 3:50 PM EST - 3 months ago

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

MRNA NVAX PFE

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

Dec 1, 2025, 12:35 PM EST - 3 months ago

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

MRNA NVAX PFE

BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration

Nov 26, 2025, 7:30 AM EST - 3 months ago

BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration

BioNTech SE (BNTX) Discusses Oncology Innovation Strategy, Combination Therapies and Personalized Cancer Immunotherapies Transcript

Nov 17, 2025, 6:17 PM EST - 3 months ago

BioNTech SE (BNTX) Discusses Oncology Innovation Strategy, Combination Therapies and Personalized Cancer Immunotherapies Transcript

Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up

Nov 13, 2025, 5:20 PM EST - 3 months ago

Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up

PFE

Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run

Nov 13, 2025, 11:10 AM EST - 3 months ago

Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run

PFE

BioNTech says collaboration with Pfizer remains unchanged

Nov 13, 2025, 8:17 AM EST - 3 months ago

BioNTech says collaboration with Pfizer remains unchanged

PFE

BioNTech Q3 Earnings: Plenty Of Cash And Pipeline Potential, But Still A Hold

Nov 3, 2025, 1:44 PM EST - 4 months ago

BioNTech Q3 Earnings: Plenty Of Cash And Pipeline Potential, But Still A Hold

BioNTech SE (BNTX) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 12:46 PM EST - 4 months ago

BioNTech SE (BNTX) Q3 2025 Earnings Call Transcript

BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership

Nov 3, 2025, 10:29 AM EST - 4 months ago

BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership

BMY

BioNTech lifts 2025 revenue guidance on BMS partnership payment

Nov 3, 2025, 6:47 AM EST - 4 months ago

BioNTech lifts 2025 revenue guidance on BMS partnership payment

BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

Nov 3, 2025, 6:45 AM EST - 4 months ago

BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

BioNTech to Host Innovation Series R&D Day on November 11, 2025

Oct 28, 2025, 7:45 AM EDT - 4 months ago

BioNTech to Host Innovation Series R&D Day on November 11, 2025

BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025

Oct 27, 2025, 7:45 AM EDT - 4 months ago

BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025

BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.

Oct 22, 2025, 6:45 AM EDT - 4 months ago

BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.

Moderna Vs BioNTech: Who's Winning The Post-COVID Race

Oct 18, 2025, 9:30 AM EDT - 4 months ago

Moderna Vs BioNTech: Who's Winning The Post-COVID Race

MRNA

BioNTech SE, InstaDeep Ltd - Special Call

Oct 1, 2025, 6:52 PM EDT - 5 months ago

BioNTech SE, InstaDeep Ltd - Special Call

BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025

Sep 23, 2025, 6:45 AM EDT - 5 months ago

BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025

Mizuho's Jared Holz: There's not much value left in vaccine stocks

Sep 19, 2025, 11:40 AM EDT - 5 months ago

Mizuho's Jared Holz: There's not much value left in vaccine stocks

MRNA NVAX PFE

COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says

Sep 12, 2025, 1:37 PM EDT - 6 months ago

COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says

JNJ KVUE MRNA PFE

BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy

Sep 8, 2025, 2:01 PM EDT - 6 months ago

BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy

BMY

BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial

Sep 8, 2025, 11:05 AM EDT - 6 months ago

BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial

BMY

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity

Sep 8, 2025, 11:00 AM EDT - 6 months ago

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity

Pfizer, partner BioNTech say updated COVID shot shows better immune response

Sep 8, 2025, 7:02 AM EDT - 6 months ago

Pfizer, partner BioNTech say updated COVID shot shows better immune response

PFE

Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula

Sep 8, 2025, 6:45 AM EDT - 6 months ago

Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula

PFE

BioNTech, Duality score initial trial win with breast cancer precision drug

Sep 5, 2025, 5:13 AM EDT - 6 months ago

BioNTech, Duality score initial trial win with breast cancer precision drug

mRNA Biotechs - Long-Term Value Risks Abound

Aug 28, 2025, 6:20 AM EDT - 6 months ago

mRNA Biotechs - Long-Term Value Risks Abound

ALNY DHR GRAL ILMN IONS MRNA RGEN

Pfizer and BioNTech's COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19

Aug 27, 2025, 12:50 PM EDT - 6 months ago

Pfizer and BioNTech's COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19

PFE

CureVac settles patent dispute litigation with Pfizer and BioNTech

Aug 7, 2025, 9:00 PM EDT - 7 months ago

CureVac settles patent dispute litigation with Pfizer and BioNTech

CVAC PFE

These Analysts Revise Their Forecasts On BioNTech After Q2 Results

Aug 5, 2025, 1:36 PM EDT - 7 months ago

These Analysts Revise Their Forecasts On BioNTech After Q2 Results

BioNTech SE (BNTX) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 1:56 PM EDT - 7 months ago

BioNTech SE (BNTX) Q2 2025 Earnings Call Transcript

BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth

Aug 4, 2025, 10:32 AM EDT - 7 months ago

BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth

BioNTech Stock Rises as Drug Maker Beats Earnings Expectations.

Aug 4, 2025, 7:01 AM EDT - 7 months ago

BioNTech Stock Rises as Drug Maker Beats Earnings Expectations.

BioNTech's Q2 revenues double on higher COVID vaccine sales

Aug 4, 2025, 6:52 AM EDT - 7 months ago

BioNTech's Q2 revenues double on higher COVID vaccine sales

BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update

Aug 4, 2025, 6:45 AM EDT - 7 months ago

BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update

Pfizer and BioNTech lose appeal in London over Moderna COVID vaccine patent

Aug 1, 2025, 4:51 PM EDT - 7 months ago

Pfizer and BioNTech lose appeal in London over Moderna COVID vaccine patent

MRNA PFE

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Aug 1, 2025, 8:31 AM EDT - 7 months ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT ALNY AMGN ARGX AZN BAX

President Trump demands drugmakers slash prices within 60 days

Aug 1, 2025, 6:54 AM EDT - 7 months ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT ALNY AMGN ARGX AZN BAX

taxplanr
taxplanr Mar. 3 at 1:00 AM
Ovarian Cancer Free in 4 months with Ivermectin and Mebendazole in Australia $BNTX $MRNA $BMY $MRK https://makisw.substack.com/p/ivermectin-and-mebendazole-testimonial-214?utm_source=post-email-title&publication_id=1385328&post_id=189706231&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
taxplanr
taxplanr Mar. 3 at 12:58 AM
$BNTX $MRNA how did I miss this? 😁 https://finviz.com/news/317385/moderna-faces-lawsuit-from-biontech-over-next-generation-covid-19-shot
0 · Reply
taxplanr
taxplanr Mar. 3 at 12:53 AM
Ivermectin and Fenbendazole taking care of Lymphona in Canada $BNTX $MRNA $BMY $MRK https://makisw.substack.com/p/ivermectin-and-fenbendazole-testimonial-c15?utm_source=post-email-title&publication_id=1385328&post_id=189650154&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
taxplanr
taxplanr Mar. 2 at 8:56 PM
Ivermectin and Fenbendazole shrinking Pancreatic Cancer Tumors in Slovakia $BNTX $MRNA $BMY $MRK https://makisw.substack.com/p/ivermectin-and-fenbendazole-testimonial-c15?utm_source=post-email-title&publication_id=1385328&post_id=189650154&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
RichMitch
RichMitch Mar. 2 at 8:39 PM
$GOSS That .35 was delicious. Yeah, Im'ma Hold this one $BNTX $UNH $LLY $SPY
0 · Reply
IndyOne
IndyOne Mar. 2 at 7:35 PM
$BNTX BioNTech (BNTX) Expected to Announce Quarterly Earnings on Monday
0 · Reply
taxplanr
taxplanr Mar. 2 at 6:38 PM
$BNTX $MRNA $BMY $MRK
1 · Reply
Ventureville
Ventureville Mar. 2 at 4:47 PM
$BIOV.CSE $BVAXF $MRNA $BNTX This is being mispriced. Biovaxys isn’t competing with PD-1, it’s targeting the patients those therapies fail, right as the class hits a 2028 patent cliff. That’s partnership territory, not head-to-head risk. Comparable deals: $50M–$200M. Current cap: ~CAD $7M. One deal changes everything.
1 · Reply
taxplanr
taxplanr Mar. 2 at 3:35 PM
$BNTX $MRNA $PFE
1 · Reply
taxplanr
taxplanr Mar. 2 at 3:17 PM
CBD Oil working with Ivermectin and Mebendazole on Glioblastoms $BNTX $MRNA $BMY $MRK https://makisw.substack.com/p/ivermectin-mebendazole-cbd-oil-testimonial-9b7?utm_source=post-email-title&publication_id=1385328&post_id=189569450&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Mar. 2 at 8:57 AM
$BNTX sitting at $110 with volume 57% below average, while $CRSP at $60 with volume 29% below average. Biotech sector in focus - which stock will see a breakout first?
0 · Reply
IndyOne
IndyOne Mar. 2 at 5:07 AM
$NVDA $174 coming. ROTATE TO $MRNA & $BNTX.
0 · Reply
IndyOne
IndyOne Mar. 2 at 5:05 AM
$NVDA Friends don't let friends drive drunk. STOP. ROTATE TO $MRNA and $BNTX.
0 · Reply
taxplanr
taxplanr Mar. 2 at 2:14 AM
Ivermectin and Fenbendazole testimonial of success against melanoma after Opdivo failed $BMY $BNTX $MRNA $MRK https://www.tiktok.com/t/ZThW1v4cF/
0 · Reply
taxplanr
taxplanr Mar. 1 at 7:06 PM
Shocking Results against stage 4 Breast Cancer with Ivermectin Mebendazole and Citrus $BNTX $MRNA $BMY $MRK https://makisw.substack.com/p/ivermectin-and-mebendazole-testimonial-ae0?utm_source=post-email-title&publication_id=1385328&post_id=189565072&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
taxplanr
taxplanr Mar. 1 at 7:03 PM
Breast Cancer Free in 3 months with Ivermectina and Mebendazole $BNTX $MRNA $BMY $MRK https://makisw.substack.com/p/ivermectin-and-mebendazole-testimonial-ae0?utm_source=post-email-title&publication_id=1385328&post_id=189565072&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
IrmaWhelton942
IrmaWhelton942 Mar. 1 at 6:25 PM
$BNTX biotech pipeline progress monitored
0 · Reply
IndyOne
IndyOne Mar. 1 at 10:30 AM
$BNTX Early BioNTech mRNA breast cancer trial delivers surprise in longtime disease control https://european-biotechnology.com/latest-news/early-biontech-mrna-breast-cancer-trial-delivers-surprise-in-longtime-disease-control/
0 · Reply
IndyOne
IndyOne Mar. 1 at 10:26 AM
$BNTX ACCELERATING PROSTATE CANCER DRUG BioNTech and partner DualityBio are accelerating the development of their B7-H3 antibody-drug conjugate into a phase 3 trial for metastatic castration-resistant prostate cancer (mCRPC). With encouraging phase 1/2 data, the partners are leveraging a lean clinical strategy, aiming to achieve success with a trial roughly half the size of the competing program from Merck & Co. and Daiichi Sankyo. https://www.fiercebiotech.com/biotech/biontech-advances-dualitybio-adc-phase-3-half-patients-merck-daiichi-rival
0 · Reply
Merlintrader
Merlintrader Mar. 1 at 7:41 AM
$BNTX https://www.merlintrader.com/biontech-se-adr/
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Mar. 1 at 3:54 AM
$BEAM at $28 while $BNTX trading at $110. BEAM showing 26% below average volume, BNTX with 57% lower volume. Both in the Genomics sector - are investors waiting for a sector catalyst to drive volume back up?
0 · Reply
TradyMcGradyy
TradyMcGradyy Feb. 28 at 10:36 AM
$BNTX $MRNA $NVAX $PFE
0 · Reply